Powell speech takes center stage in Tuesday’s economic events
Neil F. McFarlane, the President and CEO of Zevra Therapeutics, Inc. (NASDAQ:ZVRA), sold 19,500 shares of common stock on October 10, 2025, at a price of $10.8158, totaling approximately $210,908. The transaction comes amid strong momentum for ZVRA, which has seen its stock surge ~68% over the past six months and ~13% in the past week alone.
On the same day, McFarlane also exercised 50,000 Restricted Stock Units, each representing a contingent right to receive one share of Zevra Therapeutics’ common stock. The company maintains robust financial health with a current ratio of 7.85, indicating strong liquidity, while four analysts have recently revised their earnings expectations upward.
Following these transactions, McFarlane directly owns 222,016 shares of Zevra Therapeutics. For deeper insights into ZVRA’s valuation and growth prospects, including exclusive analysis and additional ProTips, check out InvestingPro.
In other recent news, Zevra Therapeutics reported its second-quarter 2025 financial results, showing a notable performance in revenue despite a miss on earnings per share (EPS). The company achieved revenue of $25.9 million, surpassing expectations by 15.16%. However, the EPS was -$0.06, which fell short of the forecasted $2.19. Additionally, MIPLYFFA sales were reported at $21.5 million, exceeding both Citizens JMP and consensus estimates of approximately $20 million. Following these results, Citizens JMP adjusted its price target for Zevra Therapeutics to $18.00 from $19.00 while maintaining a Market Outperform rating. The adjustment reflects the firm’s analysis of the company’s financial performance. These developments provide investors with insights into Zevra’s recent financial activities and market evaluations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.